可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1]MattaceRaso FU,Verwoert GC,Hofman A,et al.Inflammation and incidentisolated systolic hypertension in older adults: the Rotterdam study[J].J Hypertens,2010,28(5):892-895.
[2]Androulakis E,Tousoulis D,Papageorgiou N,et al.Essential hypertension: Is there a role for inflammatory mechanisms?[J].Cardiol Rev,2009,17(5):216-221.
[3]Braunersreuther V,Mach F,Steffens S.The specific role of chemokines in atherosclerosis[J].Thromb Haemost,2007,97(5):714-721.
[4]Rose P,Bond J,Tighe S,et al.Genes overexpressed in cerebral arteries following saltinduced hypertensive disease are regulated by angiotensin II, JunB, and CREB[J].Am J Physiol Heart Circ Physiol,2008,294(2):1075-1085.
[5]Brown NJ.Aldosterone and vascular inflammation[J].Hypertension,2008,51(2):161-167.
[6]Amiri F,Ko EA,Javeshghani D,et al.Deleterious combined effects of saltloading and endothelial cell restricted endothelin1 overexpression on blood pressure and vascular function in mice[J].J Hypertens,2010,28(6):1243-1251.
[7]Schulz E,Gori T,Münzel T.Oxidative stress and endothelial dysfunction in hypertension[J].Hypertens Res,2011,34(6):665-673.
[8]Touyz RM,Briones AM. Reactive oxygen species and vascular biology:implications in human hypertension[J].Hypertens Res,2011,34(1):5-14.
[9]Ienhuis HL,Westra J,Smit AJ,et al.AGE and their receptor RAGE in systemic autoimmune diseases:an inflammation propagating factor contributing to accelerated atherosclerosis[J].Autoimmunity,2009,42(4):302-304.
[10]Ao J,Shao Y,Lai W,et al.Association of polymorphisms in the RAGE gene with serum CRP levels and coronary artery disease in the Chinese Han population[J].J Hum Genet,2010,55(10):668-675.
[11]Tatasciore A,Zimarino M,Renda G,et al.Awake blood pressure variability, inflammatory markers and target organ damage in newly diagnosed hypertension[J].Hypertens Res,2008,31(2):2137-2146.
[12]Kim KI,Lee JH,Chang HJ,et al.Association between blood pres sure variability and inflammatory marker in hypertensive patients[J].Circ J,2008,72(2):293-229.
[13]Abkin SW.The role of interleukin 18 in the pathogenesis of hypertensioninduced vascular disease[J].Nat Clin Pract Cardiovasc Med,2009,6(3):192-199.
[14]Chujo D,Yagi K,Asano A,et al.Telmisartan treatment decreases visceral fat accumulation and improves serum levels of adiponectin and vascular inflammation markers in Japanese hypertensive patients[J].Hypertens Res,2007,30(12):1205-1210.
[15]Onal IK,Altun B,Onal ED,et al.Serum levels of MMP-9 and TIMP-1 in primary hypertension and effect of antihypertensive treatment[J].Eur J Intern Med,2009,20(4):369-372.
[16]Rigsby CS,Ergul A,Portik Dobos V,et al.Effects of spironolactone on cerebral vessel structure in rats with sustained hypertension[J].Am J Hypertens,2011,24(6):708-715.
[17]Rosei EA,Morelli P,Rizzoni D,et al.Effects of nifedipine GITS 20 mg or enalapril 20 mg on blood pressure and inflammatory markers in patients with mildmoderate hypertension[J].Blood Press,2005,14(1):14-22.
[18]Takase A,Nakazawa A,Yamashita S,et al.Pioglitazone produces rapid and persistent reduction of vascular inflammation in patients with hypertension and type 2 diabetes mellitus who are receiving angiotensin II receptor blockers[J].Metabolism,2007,56(4):559-564.
[19]Edwardsa KM,Zieglerb MG,Millsa PJ.The potential antiinflammatory benefits of improving physical fitness in hypertension[J].J Hypertens,2007,25(8):1533-1542.